ViiV's HIV shot preferred, as activists spotlight funding crisis at IAS 2025
A global specialist in HIV that is majority owned by GSK, with Pfizer and Shionogi as shareholders, ViiV announced data from the Phase IIIb VOLITION study (NCT05917509) at the International AIDS Society (IAS) conference 2025, taking place from 13 to 15 July in Kigali, Rwanda.
In the study, 89% of treatment-naïve HIV patients switched to Cabenuva (a combination treatment of cabotegravir and rilpivirine) following rapid viral suppression with daily Dovato (dolutegravir/lamivudine). Cabenuva is dosed once every two months by a healthcare professional.
Patients were initially treated with daily Dovato until they achieved viral suppression. At this point, they were offered the opportunity to change to Cabenuva.
The most common reasons cited for choosing Cabenuva were not having to worry about missing a dose each day (80%) and not having to carry medication (68%).
ViiV CMO Jean van Wyk said: 'Long-acting injectables provide options that can offer high effectiveness and tolerability, improved adherence, and a preferred dosing schedule compared with daily oral pills. We believe they are a key part of HIV treatment and prevention and will play a critical role in achieving our ambition of ending HIV and AIDS.'
Patients were initially treated with daily Dovato until they achieved viral suppression. At this point, they were offered the opportunity to change to Cabenuva.
Effectiveness was also sustained with Cabenuva in the real world, with data from several observational studies.
In these studies, Cabenuva was shown to address challenges associated with daily oral pills, offering improved treatment satisfaction, high effectiveness and a patient-preferred treatment option that supports long-term virologic control. It also provides better adherence to treatment, something which is a real issue with daily PrEP options due to stigma concerns.
GlobalData, the parent company of Clinical Trials Arena, predicts sales of Cabenuva to reach $2.83bn in 2030.
ViiV is also investigating an HIV therapy that can be dosed once every four months. In a Phase IIb trial, the therapy was able to suppress viral load below 50 copies per millimetre in blood.
Long-acting pre-exposure prophylaxis (PrEP) for HIV has been prominent on the agenda at the IAS 2025 meeting. MSD has initiated two Phase III studies of its monthly oral PrEP candidate, and Gilead is set to report more positive data from its two-Phase III studies of twice-yearly Yeztugo (lenacapavir).
On 14 July, the World Health Organization (WHO) endorsed the use of Yeztugo, saying that without a vaccine, it is the 'next best thing'.
GlobalData analysts highlighted that the approval of Yeztugo is a 'momentous step in improving PrEP options available for people vulnerable to contracting HIV'.
The main topic of conversation at the IAS 2025 conference, however, is the loss of various funding schemes which helped to provide treatment and research into HIV. Funding cuts by Trump's administration are already impacting low-income and middle-income countries, with cases of HIV already rising just six months after the reductions were made.
During IAS's opening session, a group of activists took to the stage to vocalise their anger at the loss of funding, as well as some companies removing their diversity policies that recognised patients from LGBTQ+ communities, many of whom are more susceptible to transmitting HIV. The activists chanted 'we will not be erased' as they took to the stage, with several members of the group sharing their views and experiences as HIV patients from the LGBTQ+ community.
The conference states it is welcoming of protests and that it 'endorses freedom of speech as an essential principle to end the HIV pandemic as a threat to public health'.
"ViiV's HIV shot preferred, as activists spotlight funding crisis at IAS 2025" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
2 hours ago
- Chicago Tribune
Public health officials: Ending the HIV epidemic is in sight. We can't stop now.
Thanks to decades of sustained federal investment, Chicago, Cook County and Illinois are on the cusp of ending the HIV epidemic in our city, county and state. This remarkable progress is a testament to programs such as the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, established in 1990 to provide crucial health care to those living with HIV and AIDS. This critical legislation, named in honor of young AIDS activist Ryan White, marked a turning point in our fight against HIV. It wasn't just a humanitarian response; it was sound public health policy. Within that decade, the spread of HIV, the progression of HIV to AIDS and the mortality rates due to AIDS all peaked and have been declining ever since. Funding channeled through state and city agencies such as the Illinois Department of Public Health (IDPH), the Cook County Department of Pubic Health (CCDPH) and the Chicago Department of Public Health (CDPH), alongside direct support to community organizations, made medical treatment and support services accessible, especially for low-income individuals. Coupled with Centers for Disease Control and Prevention grant programs for monitoring, testing and prevention with lifesaving tools such as the prophylaxis medicines PrEP and Doxy PEP, we've built a robust system that works. It is thanks to this funding and the work of hundreds of epidemiology teams at local health agencies including IDPH, CCDPH and CDPH that we have data that shows how many people have received an HIV diagnosis and how many people are receiving HIV care. Thirty-five years later, Chicago, Cook County and Illinois, along with the rest of the country, have seen a dramatic decrease in new diagnoses thanks to these prevention, testing and treatment programs. We also see higher percentages of those living with HIV getting vital care and treatment and living long, full lives. But this progress is fragile. To pull back now would be a catastrophic mistake, especially for our most vulnerable communities. Despite hitting a significant low in new HIV cases, the burden of HIV/AIDS still falls disproportionately on communities of color. And while medical advancements allow those living with HIV to survive and thrive, their care demands continuous, costly services. More work is needed to see basic investment and improvements to HIV monitoring and infrastructure while also making use of more advanced technology. Consider the immediate impact: In 2024 alone, nearly 14,000 Chicagoans and thousands more Illinoisans relied on Ryan White funding for their HIV care. A staggering 70% of those served by CDPH-funded programs are Black, Latino, or Hispanic — the very communities most affected by HIV/AIDS. The lifeline for these programs? Federal funding. In fact, more than 90% of CDPH's annual budget for managing infectious diseases, including HIV, comes directly from federal sources. Yet, despite this clear success and urgent need, Washington, D.C., is debating draconian cuts to these vital programs in next year's budget, even threatening to rescind funds already allocated for 2025. The consequences of these cuts would be devastating. AmfAR, the Foundation for AIDS Research, projects that a 50% reduction in HIV prevention funding from the CDC could lead to 75,000 new HIV infections across the U.S. by 2030 — and that number would nearly double if all funding is eliminated. Here in Illinois, we could face over 5,500 additional new HIV cases, leading to sicker populations and a tragic rise in deaths due to lack of treatment. Without these federal dollars, our neighbors would lose access to critical prevention tools such as PrEP, essential testing for HIV and sexually transmitted infections, and lifesaving treatments. We stand at a crossroads. We have the knowledge, tools and proven programs to end the HIV epidemic. We are so close. To retreat now, when the finish line is in sight, would be an act of profound negligence. We urge our elected officials in Washington, D.C., to reject these dangerous cuts and continue investing in the programs that protect the health and well-being of all Illinoisans. We cannot afford to backtrack and lose the tremendous progress that has been made in fighting HIV. The health of our communities depends on it.
Miami Herald
2 hours ago
- Miami Herald
Report finds ‘dehumanizing' conditions in Florida immigration detention centers
Conditions in South Florida's immigration detention centers during the Trump administration's ongoing crackdown have been described as degrading and dehumanizing—violating international human-rights standards and the U.S. government's own detention guidelines—in a newly released report by three advocacy organizations. The 92-page report, ''You Feel Like Your Life is Over': Abusive Practices at Three Florida Immigration Detention Centers Since January 2025,' was released this week by Americans for Immigrant Justice, Human Rights Watch and Sanctuary of the South. It alleges widespread mistreatment of migrants detained at the Krome North Service Processing Center, Broward Transitional Center and the Federal Detention Center in Miami. The organizations—an immigrant-rights law firm, a global human-rights watchdog and a worker-led collective—reviewed documents and interviewed 17 current and former detainees, along with family members and attorneys. Detainees described extreme overcrowding, unsanitary conditions and abusive treatment by Immigration and Customs Enforcement officers and private contractors. 'Some were shackled for prolonged periods on buses without food, water, or functioning toilets; there was extreme overcrowding in freezing holding cells where detainees were forced to sleep on cold concrete floors under constant fluorescent lighting,' the report states. 'Many were denied access to basic hygiene and medical care.' The U.S. Department of Homeland Security, Immigration and Customs Enforcement and Bureau of Prisons did not respond to the Miami Herald's requests for comment. Emergencies were ignored Medical neglect was a central theme of the findings. Detainees with diabetes, HIV, asthma, kidney conditions and chronic pain reported being denied essential medications and doctor visits. Among the cases described in the report: ▪ A man with chronic illness said he collapsed after being transferred from the Federal Detention Center in downtown Miami to the Broward Transitional Center in Pompano Beach without his required daily medication. His family discovered he had been hospitalized under a false name. He was returned to detention in shackles. ▪ One man said he coughed up blood for hours in a crowded cell. When detainees protested, a Disturbance Control Team stormed in, zip-tied them and forced them to lie face down on a wet floor. One detainee reported seeing an officer instruct colleagues to turn off the CCTV camera. Another said an officer slapped him. ▪ A man detained at Krome described collapsing from a strangulated hernia after being denied care. 'The doctor told me if I had come in any later, my intestines would've ruptured,' he said. 'I had to throw myself on the floor just to get help.' He said he also witnessed officers hogtie and beat detainees who refused to board a transfer bus after a peaceful protest. ▪ Two men said they were denied HIV treatment while detained at Krome. One, previously held at the West Miami-Dade facility in 2020 and provided daily medication, was re-arrested in February. Despite the facility having his medical records, he waited 12 days before seeing a doctor. Similarly, another man had to wait over 13 days to receive his HIV medication, causing his previously undetectable viral load to become detectable. ▪ Another woman described witnessing the death of Marie Ange Blaise, a 44-year-old Haitian woman in the Broward Transitional Center. 'We started yelling for help, but the guards ignored us,' she said. 'By the time the rescue team arrived, she wasn't moving.' READ MORE: Florida congresswomen demand answers after Haitian woman dies in ICE custody Detainees said they were made to eat while handcuffed behind their backs, according to the report. They also described retaliation for seeking mental health support. At the Broward Transitional Center, they said, people who asked for help were placed in solitary confinement for weeks. Women held at Krome, a facility meant for men, reported being confined without bedding or privacy. One woman recalled arriving late at night on Jan. 28 and being held for days in a cell that was typically used for intake procedures and had just one toilet covered in feces. 'People in immigration detention are being treated as less than human,' Belkis Wille, the report's author and associate crisis and conflict director at Human Rights Watch, said in a statement. 'These are not isolated incidents, but the result of a fundamentally broken detention system that is rife with serious abuses.' Enforcement and Detention Immigration detention has surged nationwide since the beginning of Trump's second term, leading to overcrowding. In Florida, federal and state crackdowns have driven the detained population at Krome to nearly triple in three months. The Federal Detention Center, previously unused for immigration detention, began housing hundreds of immigrants earlier this year. The report emphasizes that the current administration has shown that 'any non-citizen, not just those with criminal convictions, are prone to apprehension and detention.' It highlights that the Department of Homeland Security exercises broad authority to detain and initiate removal proceedings against anyone out of lawful status. This includes people who entered the country without authorization, overstayed tourist or work visas, had student visas revoked or lost temporary protections such as humanitarian parole or Temporary Protected Status after they expired or were terminated. The report contrasts this approach with that of Trump's previous administration, which placed less emphasis on detaining and deporting non-citizens in these categories , instead focusing more narrowly on individuals with criminal records or those deemed national security threats. The expanded scope of enforcement — and the proliferation of 287(g) agreements linking local police and corrections and federal immigration enforcement — is contributing to a 'dramatic increase in arrests and detentions,' the report states. Within a month of Trump's second term, the number of people detained by ICE began to rise. Throughout 2024, an average of approximately 37,500 people were held in immigration detention each day. By June 20, that number had climbed to over 56,000 detainees on any given day—a 40 percent increase compared to June 2024, according to Human Rights Watch analysis of ICE data. Advocates have raised serious concerns about detainee safety and access to basic services amid extreme overcrowding in Florida's immigration detention facilities. At Krome, the number of detainees surged by 249 percent by March compared to pre-inauguration levels, with the facility at times holding more than three times its operational capacity, according to Human Rights Watch report. By June 20, the total number of immigration detainees across the three facilities in Florida remained 111 percent above levels seen before President Trump's return to office, underscoring the ongoing strain on the state's detention infrastructure under the administration's intensified immigration enforcement policies. Human Rights Watch says it sent letters on May 20 and June 11 to ICE, the Federal Bureau of Prisons, and the private companies managing Krome and Broward Transitional Center, detailing their findings and requesting responses. It says only the company operating Krome replied, saying it could not comment publicly. Echoes of previous reporting The findings in the report echo conditions independently documented by the Miami Herald in recent months. The Herald interviewed three former Krome detainees, along with attorneys and family members of three others held at the west Miami-Dade complex. They described a facility pushed to the brink, with detainees living in distress. READ MORE: 'Inhumane:' Overcrowding strains Krome detention center amid Trump's immigrant crackdown Although Krome and other ICE-run detention centers are bound by strict standards covering medical, mental health, hygiene, legal access, abuse prevention and language services, immigration attorneys told the Herald that conditions at Krome are 'the worst seen in 20 years' and have 'risen to the level of an international human rights disaster.' Another Herald investigation revealed last month that migrant detainees held at the Federal Detention Center in Miami are facing harsh and potentially rights-violating conditions. The facility, primarily designed for criminal defendants, is now also housing immigrants. According to legal documents and interviews with detainees, Bureau of Prisons staff and attorneys, the center is plagued by crumbling infrastructure, frequent use of force and severely limited access to legal counsel. While some detainees say the basic living conditions are slightly better than those in nearby ICE-run detention centers, access to legal support is significantly worse. Detainees report difficulty in communicating with attorneys, making legal phone calls or preparing for court. These findings raise concerns about due process, since immigration detention is civil in nature and not meant to be punitive. The government has expanded detention capacity to federal prisons. Under a February contract, ICE began placing detainees in five Federal Bureau of Prisons facilities. Legal documents and interviews reviewed by the Herald show these immigrants face harsh conditions, deteriorating infrastructure, and limited legal access—though in some cases, facilities are better maintained than traditional ICE centers. A Feb. 7 letter from Bureau of Prisons administrators classified immigrant detainees as 'pretrial inmates,' despite their civil—not criminal—status. Recommendations According to the advocacy organizations report, the abuses described violate ICE's own Performance-Based National Detention Standards and National Detention Standards, as well as international obligations under the International Covenant on Civil and Political Rights, the Convention Against Torture and the UN's Mandela Rules. The report urges the federal government to scale back detention and adopt community-based alternatives that provide legal, housing, and healthcare support—especially for asylum seekers, people with disabilities and others in compliance with immigration proceedings. It recommends that Congress repeal mandatory detention laws, reduce ICE funding and expand legal aid and oversight. DHS and ICE are called on to end the use of prisons, jails and private facilities for civil detention, improve medical care and increase transparency. For Florida officials, the report recommends ending 287(g) agreements with local law enforcement and rejecting new detention contracts. It also calls on United Nations bodies to investigate conditions in U.S. immigration detention and hold the government accountable for rights violations.
Medscape
4 hours ago
- Medscape
Baseline Viral Load Shapes Immune Response in Women With HIV
TOPLINE: Most women living with HIV achieved an immunologic response after 2 years of initiating antiretroviral therapy. A higher baseline HIV viral load increased the odds of an immunologic response in women living with HIV, but this association diminished among those who acquired HIV through intravenous drug use. METHODOLOGY: Researchers conducted a register-based cohort study to determine the prevalence and factors associated with immunologic response in women living with HIV in Sweden. They analyzed 841 women with viral suppression (mean age, 37 years; baseline CD4 T-cell count < 500 cells per μL) diagnosed with HIV after 2000. The primary outcome was an immunologic response 2 years after initiating antiretroviral therapy among those who achieved sustained viral suppression within 6 months of treatment initiation. TAKEAWAY: Among the women studied, 90% (95% CI, 0.88-0.92) achieved an immunologic response after 2 years of follow-up. Having a baseline HIV viral load of ≥ 100,000 copies/mL increased the likelihood of achieving immunologic response (adjusted odds ratio, 1.81; 95% CI, 0.96-3.41), except in women who acquired HIV through intravenous drug use. No significant associations were found between immunologic response and baseline CD4 count, antiretroviral therapy experience, or age. IN PRACTICE: 'It supports earlier studies identifying the level of baseline HIV RNA viral load as an important factor and identifies the potential varying impact that HIV acquisition mode may have on this association,' the authors wrote. 'Future studies incorporating additional sex-specific factors are essential to refine our understanding and improve tailored clinical care strategies,' they added. SOURCE: This study was led by Josefin Nilsson, Unit of Infectious Diseases and Dermatology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. It was published online on June 12, 2025, in HIV Medicine. LIMITATIONS: This study included data only from women diagnosed after 2000. The small sample size decreased the model's power, thereby limiting the number of variables that could be included. Additionally, the study did not include information on female-specific factors, such as the use of hormonal treatments, which may have influenced immunologic response. DISCLOSURES: This study was supported by a grant from the Swedish Doctors against AIDS Research Foundation and an unrestricted Nordic Fellowship Grant from Gilead Sciences. Some authors declared receiving lecture fees or advisory board fees from various sources, including GSK/ViiV and Gilead Sciences. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
